Setmelanotide News
Setmelanotide currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Setmelanotide with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC),...
- Evidence level: L5
- Predicted indications (20):
- migraine disorder (92.2%)
- migraine with brainstem aura (91.7%)
- non-syndromic esophageal malformation (89.6%)
- esophageal disease (88.4%)
- amenorrhea (disease) (86.0%)
- cauda equina syndrome (83.0%)
- obsolete neurogenic bladder (disease) (82.2%)
- esophageal ulcer (81.4%)
- Ambras type hypertrichosis universalis congenita (81.2%)
- pituitary dwarfism (81.1%)
- migraine with or without aura, susceptibility to (80.4%)
- atrophoderma vermiculata (80.0%)
- malformation syndrome with odontal and/or periodontal component (78.9%)
- syndrome with a Dandy-Walker malformation as major feature (78.4%)
- isolated genetic hair shaft abnormality (78.0%)
- erectile dysfunction (disease) (77.9%)
- hypertrichosis (disease) (77.9%)
- ulerythema ophryogenesis (76.7%)
- acne (disease) (74.1%)
- adrenal gland hyperfunction (72.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.